Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
30-Sep-2026 | 1,060 | 1,075 | 1,033.5 | 1,047.2 | 32,209 | 51,87,88,422.3 | 2,11,704 |
01-Oct-2026 | 1,044 | 1,095 | 1,034.6 | 1,064.1 | 75,167 | 1,81,56,23,482.7 | 5,94,819 |
05-Oct-2026 | 1,069 | 1,081.9 | 1,020.2 | 1,031.2 | 35,667 | 90,70,47,337.2 | 5,71,626 |
06-Oct-2026 | 1,028.1 | 1,079.9 | 1,026.1 | 1,073.7 | 35,352 | 62,34,16,086.8 | 2,79,396 |
07-Oct-2026 | 1,072.4 | 1,086.8 | 1,055.1 | 1,071.2 | 27,531 | 46,35,22,217 | 2,01,944 |
08-Oct-2026 | 1,077.5 | 1,077.5 | 1,016 | 1,025.3 | 38,636 | 69,84,32,572.5 | 3,60,223 |
09-Oct-2026 | 1,025.4 | 1,048.2 | 991.4 | 1,021.7 | 27,604 | 40,46,67,935.5 | 1,61,598 |
12-Oct-2026 | 1,045 | 1,046.9 | 1,007.6 | 1,013.9 | 22,954 | 36,12,48,504 | 1,38,466 |
13-Oct-2026 | 1,018 | 1,024 | 935 | 973.6 | 64,339 | 1,28,66,31,316 | 6,19,680 |
14-Oct-2026 | 973 | 984.7 | 953.6 | 962.1 | 37,670 | 51,65,98,644.2 | 2,58,517 |
15-Oct-2026 | 967.9 | 969.5 | 917.5 | 922.1 | 55,258 | 77,75,77,780.3 | 4,72,978 |
16-Oct-2026 | 920 | 962 | 913 | 937.6 | 48,528 | 68,02,46,122.4 | 3,05,597 |
19-Oct-2026 | 890 | 919.9 | 855.2 | 876.2 | 1,04,112 | 2,06,98,46,303.9 | 11,25,137 |
21-Oct-2026 | 855.1 | 882.9 | 835.8 | 845.2 | 71,383 | 1,21,30,75,953.5 | 6,64,533 |
22-Oct-2026 | 826.3 | 894.2 | 820.4 | 860.8 | 64,395 | 1,29,66,07,613.5 | 4,41,420 |
23-Oct-2026 | 860.8 | 883 | 838.8 | 864.3 | 49,312 | 82,40,62,867.6 | 3,99,910 |
26-Oct-2026 | 880 | 908.9 | 860 | 900.8 | 54,136 | 77,24,94,942.3 | 3,33,344 |
27-Oct-2026 | 912.6 | 924 | 895.1 | 904.7 | 26,284 | 37,24,63,762.5 | 1,48,654 |
28-Oct-2026 | 909 | 937.3 | 906 | 932 | 30,134 | 53,02,38,103.9 | 2,99,702 |
29-Oct-2026 | 932 | 949.8 | 922.9 | 935.6 | 26,524 | 36,16,28,943.6 | 1,69,686 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
